Porphyria (EPP)

Erythropoietic protoporphyria (EPP) is Clinuvel's lead clinical indication for its drug SCENESSE® (afamelanotide).

This webpage is a portal for all information relevant to clinical studies and news relevant to EPP.

SCENESSE® is currently available by prescription to Italian citizens diagnosed with EPP (learn more here). Clinuvel has filed a marketing authorisation application for SCENESSE® for EPP with the European Medicines Agency (read more here). A Phase III study of SCENESSE® has been completed in the USA with results expected in the first half of 2013.

EPP Blog Posts

Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation...

Read More

Following on from last week’s conversation, I left off with the issues surrounding the off-label prescriptive habits by physicians and...

Read More

EPP Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now